Results 111 to 120 of about 692,791 (244)

BETA-ADRENOBLOCKER THERAPY IN ARTERIAL HYPERTENSION, METABOLIC DISTURBANCES, AND TYPE 2 DIABETES MELLITUS

Российский кардиологический журнал, 2009
The paper presents modern views on beta-blocker therapy in clinical practice. The beta-blocker group is heterogeneous in terms of clinical usage.
D. V. Nebieridze, R. G. Kulieva, V. D. Sargsyan, N. L. Vinnitskaya   +3 more
doaj  

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Persistent Beta‐Blocker Therapy Reduces Long‐Term Mortality in Patients With Acute Ischemic Stroke With Elevated Heart Rates

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Elevated heart rate in patients with acute ischemic stroke is associated with increased risk of mortality. Beta‐blocker therapy is well known to reduce heart rate.
Keon‐Joo Lee, Seong‐Eun Kim, Hyung Seok Guk, Do Yeon Kim, Beom Joon Kim, Moon‐Ku Han, Joon‐Tae Kim, Kang‐Ho Choi, Dong‐Ick Shin, Jae‐Kwan Cha, Dae‐Hyun Kim, Dong‐Eog Kim, Jong‐Moo Park, Kyusik Kang, Soo Joo Lee, Jae Guk Kim, Mi‐Sun Oh, Kyung‐Ho Yu, Byung‐Chul Lee, Keun‐Sik Hong, Yong‐Jin Cho, Jay Chol Choi, Tai Hwan Park, Sang‐Soon Park, Jee‐Hyun Kwon, Wook‐Joo Kim, Jun Lee, Kyung Bok Lee, Sung Il Sohn, Jeong‐Ho Hong, Wi‐Sun Ryu, Seung‐Young Roh, Ji Sung Lee, Juneyoung Lee, Philip B. Gorelick, Hee‐Joon Bae   +35 more
doaj   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Implementation of a Beta Blocker Protocol

, 2012
Background: Beta blockers are recommended by the American College of Cardiology/American Heart Association Guidelines for high and intermediate-risk cardiac patients undergoing non-cardiac surgery.
Heriot, Jody L
core  

Evaluation of ivabradine plus beta-blocker versus beta-blocker alone in addition to standard care in reducing hospitalization and major adverse cardiovascular event in patients with chronic heart failure: a prospective observational study in tertiary care hospital in central India

The Egyptian Heart Journal
Background In recent years, there has been an increase in cases of heart failure, ultimately leading to an increase in hospitalization for heart failure (HF) and cardiovascular mortality. The aim of our study was to evaluate ivabradine combined with beta-
Ramyaa Desingu, Shilpa Kaore, Gaurav Kandelwal, S. Balakrishnan   +3 more
doaj   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Beta-blocker under-use in COPD patients

, 2017
Kuan Pin Lim,1,2 Sarah Loughrey,1 Michael Musk,1,2 Melanie Lavender,1,2 Jeremy P Wrobel1–3 1Advanced Lung Disease Unit, Royal Perth Hospital, Perth, WA, Australia; 2Respiratory Department, Fiona Stanley Hospital, Murdoch, WA, Australia; 3School of
Loughrey S, Lavender M, Musk M, Wrobel JP, Lim KP   +4 more
core  

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Effect of beta‐blockade on mortality in patients with cardiac amyloidosis: A systematic review and meta‐analysis

ESC Heart Failure
Aims The efficacy of beta‐blockers in cardiac amyloidosis (CA) is unclear, and concerns persist that neurohormonal blockade could worsen symptoms of heart failure.
Chun Shing Kwok, Chern Hsiang Choy, Jennifer Pinney, Jonathan N. Townend, Carol Whelan, Marianna Fontana, Julian D. Gillmore, Richard P. Steeds, William E. Moody   +8 more
doaj   +1 more source